Proactive Investors - Run By Investors For Investors

Nemaura says improved continuous glucose monitor halves time needed for reliable reading

According to Nemaura, a major competitor’s product requires a two-hour ‘warm-up period’
Faz Chowdhury
The flexibility of SugarBEAT will be a key differentiating factor, according to the CEO, Dr Faz Chowdhury

Nemaura Medical Inc (NASDAQ:NMRD) said Thursday that the company has improved its SugarBEAT continuous glucose monitor to halve the time needed for a reliable reading for diabetic and prediabetic patients.

The  Loughborough, England-based medical technology company said in a press release that the time it takes for a reliable reporting of glucose levels from its skin-patch system can be reduced to 30 minutes from about an hour previously.

BIG PICTURE: Nemaura is a red hot medtech stock with a winner in its painless sugarBEAT glucose monitor

According to Nemaura, a major competitor’s continuous glucose monitor requires a two-hour “warm-up period” and is designed to be worn continuously for 10 days.

Nemaura said its advance provides flexibility for users who wish to wear the skin patch for a few hours daily.

“The flexibility of SugarBEAT will be a key differentiating factor with the potential to reach the largest number of diabetics and provides Nemaura with the opportunity to expand into new markets,” Dr Faz Chowdhury, CEO of Nemaura, said in a statement.

Diabetic population

Globally, there are more than 400 million diabetics and 1 billion prediabetics, according to Nemaura, citing PiperJaffray Co data. The annual addressable market for continuous glucose monitors for diabetics is estimated at $82 billion, with the US market estimated at $13 billion.

Shares of Nemaura slipped $0.03 to $1.04 in Thursday’s Nasdaq trading.

Last month, Nemaura announced the closing of a public offering that raised $2 million.

Contact Dennis Fitzgerald at [email protected]

View full NMRD profile View Profile

Nemaura Medical Inc Timeline

Related Articles

Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use